Session 5 – Regional Collaboration & Opportunity
Date: 25 July (Thursday) 09:00 – 12:15 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
Vice President, Commercial Service
Eric Shao is the VP of the commercial services IQVIA GC. He has extensive industry commercial experience in the pharmaceutical, Med-device and healthcare industries in China and APAC. His project experience covers enterprise growth strategy, R&D and product portfolio strategy, pricing and reimbursement strategy, business distribution etc, help customers to fully implement the development strategy on R&D, product, brand, marketing, finance and operations.
Eric Shao also focus on investment, development and commercialization of biopharmaceuticals and emerging medical technologies。He participated overseas financing, market assessment and investment development strategy projects for many EBPs.
Eric Shao was head of health, customer goods and retail research in McKinsey before he joined in IQVIA. He was strategy director of Ominicom Interbrand, responsible for corporate brand strategy, digital strategy and new product launch strategy on pharmaceutical.
Eric Shao got master's degrees in Corporate Finance, public health management, management and MBA from Fudan University and Norwegian Business School, and Washington University..
Session Speech Title & Synopsis: Emerging Market Opportunities and New Dynamics for Innovation
US, Japan and EU countries are traditionally the first launch markets of innovative drugs. With the fast growing of emerging markets, innovative drugs are seeking early new launches opportunities to fully capture market potentials. However, the regulatory, market access and reimbursement environment are diversified, for example in China, faster access and price cut through national negotiation has led the new dynamics for the new launches. In the meantime, local emerging bio-pharmas are developing to join the game play and competitive landscape becomes more dynamics. This speech will cover the topics of overall market picture, policy dynamics and competition in the new dynamics as well as some advice on how to deal with the uncertain of commercial risks for bio-pharmas.